Prometheus Labs, UCLA Collaborate on IBD Markers
December 10, 2010
Prometheus Labs, UCLA Collaborate on IBD Markers
Jonathan Braun's laboratory will use a cross-sectional study to correlate genotoxicity markers to mucosal healing and disease activity in IBD patients, while Prometheus will assess other markers associated with the diagnosis and prognosis of IBD.
Full-text access for registered users only.
Existing users login here.
New to GenomeWeb? Register here quickly for free access.
New to GenomeWeb? Register here quickly for free access.
Related Stories
- UCLA Team Builds Microfluidic Platform for Measuring Protein Kinase Activity
November 19, 2010 / ProteoMonitor - Prometheus Labs, Medco Research Partner on Companion Dx for IBD
August 15, 2011 / GenomeWeb Daily News - Helicos Expands Licensing Deal with Arizona Technology Enterprise
August 30, 2011 / GenomeWeb Daily News - FDA Clears Abbott's Companion Dx for Pfizer's NSCLC Drug
August 29, 2011 / GenomeWeb Daily News - NCI Kicks Off Second Stage of Clinical Proteomic Technologies for Cancer Initiative
August 26, 2011 / ProteoMonitor